创新不容造假，只有挤干水分，才能遏制假专利，保护真创新，促进技术进步和经济社会发展，为科技 强国建设奠定坚实基础。 来源：经济日报 作者: 李璐亚 在二手交易平台搜索"专利代申请"，一条灰色产业链随之浮现：无需技术交底、不用撰写材料，只要付 款就能成为专利发明人。这类店铺月销量达数百单，客户涵盖企业职员、高校师生甚至科研人员，所售 专利多用于评职称、保研加分、申报高新技术企业等。 专利是科技创新的结晶，当假专利流入项目评审等关键环节，将占用宝贵的审查资源。一些企业甚至凭 借虚假专利套取税收优惠、财政补贴等，严重扰乱公平竞争的市场环境。长此以往，踏实创新的企业被 边缘化，投机取巧者却获利颇丰，创新积极性必将受损。 此前，国家知识产权局、公安部、市场监管总局联合印发了《关于联合开展知识产权代理行业专项整治 行动的通知》，明确要依法从严查处严重违法代理机构和从业人员，规范不正当知识产权买卖行为。要 推动相关措施落实到位，多管齐下，标本兼治，营造良好的行业发展环境。 要优化政策导向，坚决破除"唯专利数量论"，在科研评价、职称评定、高新技术企业认定中，增加专利 质量、转化效益和实际技术贡献的权重；要强化源头治理，完善专 ...

创新不容造假，只有挤干水分，才能遏制假专利，保护真创新，促进技术进步和经济社会发展，为科技 强国建设奠定坚实基础。（作者：李璐亚 来源：经济日报） 专利是科技创新的结晶，当假专利流入项目评审等关键环节，将占用宝贵的审查资源。一些企业甚至凭 借虚假专利套取税收优惠、财政补贴等，严重扰乱公平竞争的市场环境。长此以往，踏实创新的企业被 边缘化，投机取巧者却获利颇丰，创新积极性必将受损。 此前，国家知识产权局、公安部、市场监管总局联合印发了《关于联合开展知识产权代理行业专项整治 行动的通知》，明确要依法从严查处严重违法代理机构和从业人员，规范不正当知识产权买卖行为。要 推动相关措施落实到位，多管齐下，标本兼治，营造良好的行业发展环境。 要优化政策导向，坚决破除"唯专利数量论"，在科研评价、职称评定、高新技术企业认定中，增加专利 质量、转化效益和实际技术贡献的权重；要强化源头治理，完善专利申请审查机制，引入大数据分析、 技术专家等多元力量参与评审，提升识别虚假专利的精准度；要加大惩戒力度，对参与造假的申请人、 代理机构等依法追责，提高违法成本；要畅通监督渠道，鼓励社会公众举报专利造假行为，完善举报受 理与反馈机制，让灰 ...

□朱昌俊 当前市场上，隐藏式车门把手是众多车企热衷的设计元素之一。当科技感与安全性冲突时，安全性必须 拥有绝对优先的地位。近日，工业和信息化部组织制定的强制性国家标准《汽车车门把手安全技术要 求》（GB 48001—2026）由国家市场监督管理总局、国家标准化管理委员会批准发布，将于2027年1月 1日起实施。 该标准系统规定了车门把手的机械释放配置、开启逻辑、布置区域、操作空间，以及车内把手的标识与 操作说明等要求。对消费者而言，新规的核心可归纳为三点：确保碰撞后车门可开启、保障断电等故障 状态下能机械解锁、使操作方式直观易懂。如针对备受争议的隐藏式门把手，新标准明确要求其在任意 状态下，都必须提供最小为60mm×25mm×20mm的手部操作空间。这一具体尺寸要求，实质上对现有大 多数完全平整或需要电动弹出的隐藏式设计形成了技术否决，意味着此类形态的门把手将难以满足标 准，面临全面改造或淘汰。 客观而言，新能源汽车行业经历了高速成长期，其中必然伴随试错与探索，不必因为这些既有的问题就 否定行业的整体发展趋势。而从企业的自发探索到规则的纠偏也表明，行业的健康发展，既需要企业的 自律，也离不开监管的持续完善。总 ...

Core Viewpoint - The recent adjustment of the National Medical Insurance Drug List and the Commercial Health Insurance Innovative Drug List signifies the successful completion of the annual national medical insurance drug negotiation process, emphasizing the goals of "filling gaps, encouraging innovation, and optimizing structure" [1][10]. Group 1: Drug List Adjustments - A total of 114 new drugs were added to the list, with 111 being newly launched within the last five years, representing 97.3% of the additions, including 50 first-class innovative drugs [2][11]. - The total number of drugs in the directory has increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines, significantly enhancing the coverage for critical areas such as cancer, chronic diseases, and rare diseases [2][11]. - The new directory includes drugs that address gaps in basic medical insurance, such as treatments for triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as medications for rare diseases and chronic conditions [2][11]. Group 2: Support for Innovation - The negotiation success rate for this year reached 88.19%, the highest in recent years, with 127 drugs participating and 112 achieving success, indicating a strong support for genuine innovation [4][13]. - The selection process for drugs involved strict evaluations, with only 41.48% of the 331 drugs reviewed passing the expert assessment, reflecting a focus on high-quality submissions [5][14]. - The pricing assessment for drugs is based on their clinical value, with a higher willingness to pay for drugs that demonstrate significant clinical benefits, aligning with the principle of "paying more for quality life" [6][14]. Group 3: Commercial Health Insurance - The first version of the commercial health insurance innovative drug directory includes 19 high-priced innovative drugs, aimed at establishing a multi-tiered insurance system [8][16]. - The directory is designed to enhance the attractiveness of insurance products, potentially increasing the insurance uptake and improving the profitability structure of insurance companies [9][17]. - The commercial insurance directory complements the basic medical insurance list, facilitating a clearer distinction in coverage and promoting the development of a multi-layered medical insurance system [9][17].

Core Insights - The success rate of negotiations for the National Essential Medicines List reached 88% in 2025, a significant increase from 76% the previous year, marking a seven-year high [1] - A total of 114 new drugs were added to the list, including 50 innovative first-class drugs, indicating a record number both in terms of proportion and quantity [2] - Nearly 100 drugs (98) were rejected during the formal review stage, with over 60% failing to pass expert evaluation, reflecting a continuous decline in the approval rate [1][4] Group 1: Negotiation Process and Outcomes - The negotiation process has matured over the past eight years, involving self-application by pharmaceutical companies, expert evaluations, and price negotiations, resulting in 718 submissions and 535 passing the formal review [2] - The expert evaluation phase saw a pass rate of 41.48%, with 129 drugs proceeding to negotiations, of which 112 were successfully included in the National Essential Medicines List [2] - The total number of drugs in the list increased to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines [8] Group 2: Reasons for Rejection - The decline in approval rates for drugs in the expert evaluation phase is attributed to increased clarity in application processes and heightened competition among similar drugs [4] - Several rejected drugs included first-class innovative drugs, with reasons such as lack of significant clinical value compared to existing treatments [5] - Four main reasons for rejection were identified: lack of innovation, high prices, and insufficient clinical necessity [6] Group 3: Support for True Innovation - The focus on "true innovation" emphasizes filling clinical gaps, offering superior alternatives, and providing better cost-effectiveness [7] - Successful new entries into the list included innovative treatments for various cancers and chronic diseases, reflecting a commitment to enhancing healthcare coverage [8] - The National Healthcare Security Administration aims to maintain a dynamic adjustment of the drug list to meet evolving clinical needs [8] Group 4: Value-Based Purchasing - The negotiation process incorporates a systematic value assessment, including expert evaluations and price calculations, to ensure fair pricing [9] - Recent improvements in price calculation methods aim to enhance fairness and scientific rigor in the evaluation process [10] - The emphasis on differentiated innovation requires pharmaceutical companies to provide substantial clinical evidence to support claims of added value [11]

Core Insights - The approval rate for drugs outside the national essential drug list has reached a four-year low during the expert review phase, indicating increasing scrutiny and higher standards for innovation [1][4] - The success rate for negotiations in the upcoming 2025 national essential drug list has improved to 88%, up from 76% the previous year, marking a seven-year high [1] - A total of 114 new drugs will be added to the national essential drug list, including 50 innovative first-class drugs, reflecting a significant increase in both quantity and quality [2][8] Group 1: Approval Rates and Trends - The approval rate for drugs in the expert review phase has declined for two consecutive years, with only 41.48% of drugs passing this stage this year [2][3] - In the past three years, the number of drugs passing the formal review has increased, but the expert review approval rate has decreased from 74.2% to 47.0% [3] - Nearly 60% of drugs outside the essential list failed to pass the expert review, highlighting a trend towards stricter evaluation criteria [1][4] Group 2: Reasons for Non-Approval - Several drugs, including first-class innovative drugs, were not approved due to lack of significant clinical value compared to existing treatments [5][6] - The "Four No Changes" principle (no change in active ingredient, indication, administration route, or clinical value) has been identified as a key reason for low approval rates [6] - High prices and mismatched value with existing treatments have also contributed to the rejection of certain drugs, with examples of significant price discrepancies noted [6] Group 3: Support for True Innovation - The national healthcare authority emphasizes support for "true innovation" and "differentiated innovation," aiming to exclude drugs that do not significantly advance clinical outcomes [5][7] - Successful drugs entering the essential list share common characteristics such as filling therapeutic gaps and offering superior alternatives [7] - The overall speed and quantity of innovative drugs entering the national essential drug list have increased, addressing various medical needs including major diseases and rare conditions [8] Group 4: Value-Based Pricing and Evaluation - The negotiation process for the national essential drug list has evolved to include a more systematic and scientific value assessment, enhancing fairness and rigor in price evaluations [10] - The approach to pricing has shifted to support higher payment thresholds for drugs with greater innovation, reflecting a value-based pricing model [10][11] - The importance of robust clinical evidence in supporting claims of additional benefits for new drugs has been highlighted, particularly in competitive therapeutic areas [11][12]

Core Viewpoint - The National Intellectual Property Administration has introduced the "Implementation Measures for Promoting the Development of the Private Economy through Intellectual Property" to address the intellectual property bottlenecks hindering innovation in private enterprises, thereby laying a solid institutional foundation for high-quality development [1] Group 1: Addressing Innovation Concerns - Many private enterprises, especially small and medium-sized technology firms, are hesitant to innovate due to concerns about high costs, long durations, and difficulties in proving infringement when protecting their innovations [2] - The new measures aim to optimize the intellectual property environment by enhancing the quality and efficiency of reviews, implementing demand-based reviews, and providing one-stop services for pre-examination, confirmation, and rights protection through 129 national-level intellectual property protection centers [2] Group 2: Combating "Pseudo-Innovation" - Some companies engage in "patenting for the sake of patenting," leading to misallocation of resources towards low-quality applications [3] - A joint initiative by the National Intellectual Property Administration, the Ministry of Public Security, and the State Administration for Market Regulation aims to regulate the intellectual property agency industry to curb non-genuine patent applications and transactions not aimed at industrialization [3] - The revised "Patent Examination Guidelines," effective January 1, will further regulate the abuse of patent invalidation procedures to maintain a normal patent application order [3] Group 3: Promoting Genuine Innovation - The measures encourage private enterprises to convert intellectual property through various methods such as self-implementation, equity participation, transfer, licensing, and pledging, facilitating the transition of intellectual property from "paper" to "market" [4] - The industrialization rate of invention patents in China has increased from 44.9% in 2020 to 53.3% in 2024, indicating significant potential in the application phase [4] - The core strategy of the new policies is to drive innovation resources into high-quality development through a systematic approach of "protection, guidance, and application," thereby enhancing the innovation cycle within the private economy [4]

Core Viewpoint - The introduction of the commercial insurance innovative drug directory will create a win-win situation for patients, insurance companies, and hospitals, allowing patients access to innovative drugs, insurance companies to benefit from discounts, and hospitals to enhance their diagnostic capabilities and influence [1][7]. Summary by Sections Commercial Insurance Directory Release - On December 7, the National Medical Insurance Administration released the adjusted national basic medical insurance directory and the first version of the commercial insurance innovative drug directory, adding 114 new drugs to the basic insurance directory and 19 drugs to the commercial insurance directory [2]. Support for Innovation - The National Medical Insurance Administration aims to clarify the boundaries of basic medical insurance coverage and leave room for the development of commercial insurance, focusing on supporting true and differentiated innovations rather than redundant innovations [3][15]. Drug Selection Criteria - The drugs included in the commercial insurance directory are characterized by high innovation, significant clinical value, non-replaceability by existing basic insurance drugs, and strong insurability [6][11]. Market Dynamics - The commercial insurance directory is expected to provide coverage primarily for high-cost treatments after second and third-line therapies, indicating that it is designed to supplement existing basic insurance rather than simply overlap with it [7][10]. Insurance Product Development - Insurance companies are encouraged to design products that align with the commercial insurance directory, focusing on specific populations and innovative drugs [8][10]. Challenges and Considerations - The main challenges for commercial insurance include improving the efficiency of claims processing, ensuring that products cover truly innovative drugs, and addressing the potential issue of adverse selection if sick individuals are more inclined to purchase insurance [12][13]. Future Outlook - The commercial insurance directory is expected to officially launch on January 1, 2026, with insurance companies likely to introduce corresponding products shortly thereafter [10][12]. Regulatory Support - The National Medical Insurance Administration is committed to supporting true innovation and has implemented stricter evaluation criteria for new drugs, resulting in a lower approval rate for submissions [16][18]. Financial Impact - As of October 2025, the medical insurance fund has paid over 460 billion yuan for negotiated drugs, benefiting over 1 billion patients and driving related sales exceeding 670 billion yuan, demonstrating substantial financial support for the development of innovative drugs [18].

Core Insights - The National Healthcare Security Administration (NHSA) has released an updated National Basic Medical Insurance (BMI) catalog, adding 114 new drugs, and a first version of the commercial insurance innovative drug catalog, which includes 19 drugs. This dual catalog aims to clarify the boundaries of basic insurance coverage and create space for the development of commercial insurance, contributing to a diversified medical security system [1][2]. Group 1: Commercial Insurance Catalog Implementation - NHSA emphasizes three considerations for the implementation of the commercial insurance catalog: enhancing communication with local authorities, maintaining drug market prices while providing discounts to insurance companies, and encouraging the design of commercial health insurance products targeting the innovative drug catalog [2][3]. - The commercial insurance catalog includes 19 drugs, with a strict selection process resulting in a less than 20% approval rate for drugs entering the price negotiation phase, indicating a rigorous expert review [3][4]. Group 2: Characteristics of Included Drugs - The drugs in the commercial insurance catalog exhibit four main characteristics: high innovation level, significant clinical value, non-replaceability by existing BMI catalog drugs, and strong insurability [4][5]. - Most drugs included are for second-line and third-line treatments, highlighting the catalog's focus on providing coverage for high-cost treatments of catastrophic diseases beyond existing BMI coverage [5][6]. Group 3: Stakeholder Benefits and Challenges - The commercial insurance catalog is expected to create a win-win situation for patients, insurance companies, and hospitals, allowing access to innovative drugs while providing discounts to insurers and enhancing hospital capabilities [6][7]. - Challenges identified include the need for better integration between commercial insurance and medical institutions, improving claims efficiency, and ensuring that product designs adequately cover truly innovative drugs [6][8]. Group 4: Future Developments and Considerations - The commercial insurance catalog is anticipated to officially launch on January 1, 2026, with insurance companies expected to quickly develop corresponding products. However, the timeline for public access to these products remains uncertain [8][9]. - The potential for insuring individuals with pre-existing conditions is noted, but concerns about adverse selection in the insurance market are raised, emphasizing the need for careful management of pricing and claims data [9][10]. Group 5: Support for True Innovation - The NHSA has increased support for innovative drugs in the BMI catalog, with 50 out of 114 new drugs being classified as first-class innovative drugs, reflecting a significant commitment to fostering true innovation in the pharmaceutical sector [11][12]. - The approval process for drugs has become more stringent, with a lower approval rate for expert reviews, indicating a focus on supporting differentiated innovations rather than redundant ones [12][13].

Core Viewpoint - Yiling Pharmaceutical's innovative traditional Chinese medicine, Qifang Nasal Tablets, has been included in the national medical insurance catalog for the first time, providing a new treatment option for patients with allergic rhinitis [1][2]. Group 1: Product and Innovation - Qifang Nasal Tablets is a Class 1 innovative drug aimed at treating persistent allergic rhinitis, which affects over 200 million patients in China, with a prevalence rate of 17% [3]. - The inclusion of Qifang Nasal Tablets in the national medical insurance directory is a recognition of its innovation, clinical efficacy, and safety [2]. - The formulation of Qifang Nasal Tablets is based on traditional Chinese medicine theories, integrating classic prescriptions and innovative ingredients to address both symptoms and underlying causes of allergic rhinitis [3][4]. Group 2: Clinical Efficacy and Research - The efficacy and safety of Qifang Nasal Tablets have been validated through rigorous clinical trials, including randomized, double-blind, placebo-controlled studies published in an international SCI journal [4]. - The clinical trials demonstrated a total effective rate of 74.71% in symptom improvement, with a patient satisfaction improvement rate of 89% [4]. - The drug exhibits multiple pharmacological effects, including anti-allergic, anti-inflammatory, and immune regulation, supporting its comprehensive treatment approach [4]. Group 3: Market Position and Competitors - Qifang Nasal Tablets offers a holistic regulatory advantage over other treatments for allergic rhinitis, addressing nasal, ocular, and systemic symptoms effectively [5]. - In addition to Qifang Nasal Tablets, Yiling Pharmaceutical has 11 other proprietary products included in the new medical insurance directory, enhancing its market presence [5].